Genetic Risk Score Prevents Unnecessary Prostate Cancer Workups Genetic Risk Score Prevents Unnecessary Prostate Cancer Workups
The investigators call for this risk score to be integrated into routine care. The study was published on medRxiv.org as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Racism in Medicine: But Where Do You Really Come From? Racism in Medicine: But Where Do You Really Come From?
Bishal Gyawali, MD, PhD, looks at the pervasiveness of racism in medicine, and how misunderstanding can come into play.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 28, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Monotherapy or One-Two Punch Against EGFR-Mutant NSCLC? Monotherapy or One-Two Punch Against EGFR-Mutant NSCLC?
Standard of care for patients with EGRF+ lung cancer is treatment with an EGRF targeted drug, but should this be monotherapy, or should it be combined with chemotherapy and/or other drugs?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 28, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Irrational Fear Is Killing You Irrational Fear Is Killing You
There is another pandemic that kills people every day. And it was completely avoidable.Medscape Blogs (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 28, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology Blog Source Type: news

Some US Women Not Getting ET for Curable Breast Cancer Some US Women Not Getting ET for Curable Breast Cancer
A novel study shows large geospatial variations across the United States in endocrine therapy (ET) for early breast cancer, showing that many women are being undertreated.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 28, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Decades of Research Fail to Resolve Disparities in GI Cancer Care Decades of Research Fail to Resolve Disparities in GI Cancer Care
Men and White people receive better treatment for gastroesophageal cancer than women, Blacks, and Latinos despite years of studies highlighting disparities in care, researchers say.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Endoscopic Mucosal Resection Valuable for Cancer Diagnosis Endoscopic Mucosal Resection Valuable for Cancer Diagnosis
Surgeons should perform EMR for all visible lesions in the presence of neoplasia to make an accurate histopathologic diagnosis of early-stage esophageal cancer, said a physician at GICS 2022.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ripretinib Safer Than Sunitinib for GIST, Fails to Improve PFS Ripretinib Safer Than Sunitinib for GIST, Fails to Improve PFS
The findings suggest that ripretinib (Qinlock) provides a similar PFS benefit but may come with notably better tolerability compared with sunitinib.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel Treatment Shows Early Promise for Gastric Cancer Novel Treatment Shows Early Promise for Gastric Cancer
A novel antibody acting on both PD-1 and CTLA4 has shown activity in first-line treatment of gastric and gastroesophageal junction cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oxaliplatin Add-On Not Recommended for Elderly With Colon Cancer Oxaliplatin Add-On Not Recommended for Elderly With Colon Cancer
The addition of oxaliplatin does not extend progression-free survival in elderly patients with metastatic colorectal cancer and in fact, can lead to more severe adverse events.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cancer Deaths Continue to Fall in EU, UK, Led by Ovarian Cancer Cancer Deaths Continue to Fall in EU, UK, Led by Ovarian Cancer
Mortality rates from most major cancers are predicted to continue falling in Europe and the UK in 2022, with a particularly striking reduction in deaths from ovarian cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Are Cancer Patients Better Off in a Clinical Trial? Are Cancer Patients Better Off in a Clinical Trial?
Many physicians believe that receiving treatment in a cancer clinical trial leads to better care and outcomes, but there is no strong evidence to support this idea.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Abraxane Still in Short Supply for Cancer Patients Abraxane Still in Short Supply for Cancer Patients
Abraxane, an albumin-bound form of paclitaxel used in the treatment of several cancers, is in short supply because of manufacturing delays.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MRI Predicts Response to VEGF Inhibitor in Recurrent Glioblastoma MRI Predicts Response to VEGF Inhibitor in Recurrent Glioblastoma
Predicting the response to therapy comes down to contrast enhancing patterns on the pretreatment MRI, a new study suggests. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Pembro+Chemo as First-Line Standard of Care for Esophageal Cancer Pembro+Chemo as First-Line Standard of Care for Esophageal Cancer
An additional 12 months of follow-up confirmed the benefits of the combination therapy as a first-line treatment for advanced or metastatic esophageal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 21, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news